Compare Neurocrine Biosciences Inc (NBIX) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Open Text Corporation — how do they compare? Neurocrine Biosciences Inc trades at $156 (market cap $16.46B), while Open Text Corporation trades at $23.97 (market cap $5.80B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.8× Open Text Corporation's market cap, and Open Text Corporation pays a 4.67% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | OTEX | |
|---|---|---|
Market Cap | $16.46B | $5.80B |
Sector | Health | Technology |
52-Week High | $185.50 | $39.69 |
52-Week Low | $123.10 | $20.01 |
Enterprise Value | $16.48B | $10.81B |
Dividend Yield | — | 4.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
Open Text Corporation (OTEX) trades at $23.95, down 3.11% over the past day. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company shows strong profitability with a 73.74% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights Q4 2026 results with cloud revenue growth and strategic investments in AI.
The investment outlook is positive given attractive valuations like a P/E of 9.29 and a consensus price target of $29.33 implying significant upside. Key risks include execution of growth initiatives and competitive pressures in the software sector. Analyst sentiment is mixed but leans cautious with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
